Akhil Santhosh, Medical Oncologist at Dr BR Ambedkar Institute Rotary Cancer Hospital, shared a post on X:

“Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.

Small randomised phase 2 trial
Used durva only in neoadjuvant phase with nab pacli and dose dense EC

Authors: S. Loibl, A. Schneeweiss, J. Huober, M. Braun, J. Rey, J.-U. Blohmer, J. Furlanetto, D.-M. Zahm, C. Hanusch, J. Thomalla, C. Jackisch, P. Staib, T. Link, K. Rhiem, C. Solbach, P.A. Fasching, V. Nekljudova, C. Denkert, M. Untch.

Neoadjuvant durvalumab improves survival in early TNBC independent of pathological complete response

One seperate window cohort where single dose of durva given 2 weeks prior
Primary endpoint point was PCR, study was heavily powered for the same, which was not met(insignificant increase)
Improved Disease-Free Survival, DDFS and Overall Survival, but all are exploratory analyses with no relevant meaning
Improvement in path Cr irrespective of PDL1 expression, Residual Stromal TILS prognostic for improved IDFS .”